Wells Fargo & Company MN Increases Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Wells Fargo & Company MN increased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 14.4% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,237 shares of the specialty pharmaceutical company's stock after acquiring an additional 7,961 shares during the quarter. Wells Fargo & Company MN owned 0.11% of Supernus Pharmaceuticals worth $2,287,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 870 shares in the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $52,000. Headlands Technologies LLC raised its stake in Supernus Pharmaceuticals by 203.0% during the 4th quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company's stock worth $55,000 after buying an additional 1,015 shares during the period. Newbridge Financial Services Group Inc. bought a new position in Supernus Pharmaceuticals in the fourth quarter worth approximately $72,000. Finally, Venturi Wealth Management LLC acquired a new stake in Supernus Pharmaceuticals in the fourth quarter valued at approximately $92,000.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SUPN. StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, April 17th. Cantor Fitzgerald restated a "neutral" rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a report on Wednesday, February 26th.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded up $0.24 on Tuesday, hitting $32.49. The company had a trading volume of 216,967 shares, compared to its average volume of 494,010. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of 30.36 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The stock has a 50 day moving average of $31.92 and a 200-day moving average of $35.01.

Insider Buying and Selling

In related news, VP Padmanabh P. Bhatt sold 9,477 shares of the firm's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at $402,915.30. This trade represents a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Jonathan Rubin sold 927 shares of the company's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total transaction of $36,292.05. Following the completion of the sale, the senior vice president now directly owns 7,853 shares of the company's stock, valued at $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.30% of the stock is currently owned by corporate insiders.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.